|
|
|
|
|
|
|
|
|
10.11.25 - 22:06
|
Myomo Reports Third Quarter 2025 Financial and Operating Results (Business Wire)
|
|
|
Revenue of $10.1 million
229 authorizations and orders, highest number this year
Reiterates full year revenue guidance of $40 million to $42 million
Conference call begins today at 4:30pm Eastern timeBURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and nine months ended September 30, 2025.
“Third quarter revenues were at the high end of our expectations, with International and U.S. orthotics and prosthetics ("O&P") revenues at record levels. Revenue increased while operating expenses decreased on a sequential basis, reflecting our focus on improving operating leverage," said Paul R. Gudonis, Myomo's Chairman and Chief Executive Officer. "We also achieved our strongest quarter of the year for authorizations and orders, while the marketing ...
|
|
|
|
|
|
|
|
|
|
|
11.08.25 - 22:09
|
Myomo Reports Second Quarter 2025 Financial and Operating Results (Business Wire)
|
|
|
Revenue of $9.7 million
816 patients added to the MyoPro pipeline
Updates 2025 revenue guidance
Conference call begins today at 4:30pm Eastern timeBURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2025.
Financial and operating highlights for the second quarter of 2025 include the following (all comparisons are with the second quarter of 2024 unless otherwise indicated):
Revenue was $9.7 million, up 28%; 56% of revenue was from Medicare Part B patients.
Revenue units were 178, up 13%; 53% of revenue units were from intra-quarter authorizations and orders
Orders and insurance authorizations were received for 207 MyoPro units, down 3%;
Backlog, which represents insurance authorizations and orders received but not yet converted to reven...
|
|
|
04.08.25 - 22:06
|
Myomo to Report Second Quarter 2025 Financial Results on August 11 (Business Wire)
|
|
|
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the second quarter of 2025 on Monday, August 11, 2025. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.
Participants are encouraged to pre-register for the conference call using this link to receive a dial-in number and PIN to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those unable to pre-register can participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call can be accessed at https://ir.myomo.com/.
A replay of the webcast will be available beginning approximately one hour after the completion of...
|
|
|
|
|
|
|
|
|
07.05.25 - 23:12
|
Myomo Reports First Quarter 2025 Financial and Operating Results (Business Wire)
|
|
|
Revenue of $9.8 million
Record 700 patients added to the pipeline
More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training
Conference call being held today at 4:30pm Eastern time
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025.
Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated):
Revenue was $9.8 million, up 162%;
Revenue units were 182, up 100%; 45% of revenue units were from first quarter authorizations and orders
Medicare Part B patients represented 59% of first quarter 2025 revenue;
Orders and insurance authorizations were received for 213 MyoPro units, up 18%;
Backlog, which represen...
|
|
|
30.04.25 - 22:09
|
Myomo to Report First Quarter 2025 Financial Results on May 7 (Business Wire)
|
|
|
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025.
The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.
Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register may dial in by calling, 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of t...
|
|
|
10.04.25 - 14:33
|
Myomo Announces Upcoming Changes to its Board of Directors (Business Wire)
|
|
|
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the board they will not stand for re-election as Class II directors. Ms. Knapp has been a director since July 2016 and Mr. Jacobovitz has served on Myomo's board since January 2023. Their terms will conclude as of the Company's 2025 Annual Meeting expected to be held in June 2025.
“I'm grateful for the insights and contributions Amy and Yitz have provided the board during their tenures, and extend deepest thanks to both for their work on behalf of Myomo, our shareholders and the patients we serve,” said Paul R. Gudonis, chairman and chief executive officer. “We plan to name additional directors in the future as we continue to evolve Myomo's governance and strategic oversi...
|
|
|
|
|
|
|
10.03.25 - 21:09
|
Myomo′s Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million (Business Wire)
|
|
|
Generated first-ever positive quarterly cash flow from operations
Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline
Introduces 2025 revenue guidance of $50 million to $53 million
Conference call being held today at 4:30pm Eastern time
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024.
Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of 2023 unless otherwise indicated):
Revenue was a record $12.1 million, up 154%;
Revenue units were a record 220, up 106%;
Positive cash flow from operations of $3.4 million; excluding net proceeds from the Company's equity offering in December 2024 and including capit...
|
|
|
03.03.25 - 22:06
|
Myomo to Report Fourth Quarter 2024 Financial Results on March 10 (Business Wire)
|
|
|
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on March 10, 2025.
The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer.
Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register may dial in by calling, 844-707-6932 (U.S.) or 412-317-9250 (International)...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
